Seven federal agencies—the Department of Defense (DOD), DOE’s National Nuclear Security Administration (NNSA), FDA, NIH, NIST, NSF and Department of Veterans Affairs (VA)—conducted or funded research in regenerative medicine from fiscal 2012–14 (FY12–14). The agencies invested about $2.89 billion in the research during this time, with the NIH accounting for about 88% of this spending. The DOD, VA and NSF invested 9%, 1% and 1%, respectively. The largest share of the NIH’s investment in regenerative medicine research, about 24%, was from its National Heart, Lung and Blood Institute. The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, and the National Institute of Neurological Disorders and Stroke each funded over $200 million in research in FY12–14. The DOD’s investment was used for health needs of active-duty military personnel, with the Defense Health Program as the largest funder. The VA’s funds went to clinicians focused on improving veterans’ health. The NSF and NNSA’s research supported basic research, the FDA’s projects focused on science for regulating regenerative medicine products, and the NIST conducted research to improve science and standards for measurement within regenerative medicine.

Source: Government Accountability Office